If you have been reading about WADA and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-14. Numbers and descriptions here follow the published literature rather than marketing material.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 317318-70-0 | Unique identifier for the compound. |
| Chemical class | PPARδ agonist | Synthetic ligand for peroxisome proliferator-activated receptor delta. |
| Appearance | White to off-white solid | Typical form of research-grade material. |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water. |
| Typical storage | -20°C | Recommended for long-term storage of stock solutions. |
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
=== Emergency medicine === He accepted a position as director of an emergency room at the University of Virginia, where he made several advances in emergency care: an emergency medical communication system for ambulances, emergency training for ambulance attendants, a rape crisis center, a crisis center for the deaf, a poison control center, an advanced life support emergency medical system, and the first medical air transport system in the Commonwealth of Virginia. Edlich was one of eight physician technical advisors for the Department of Emergency Medical Services of the US Department of Health Education and Welfare to develop emergency medical systems throughout the US. He supervised the development of emergency medical systems in the Virginia, Pennsylvania, West Virginia, Maryland, Washington DC, and Puerto Rico. In 1979, Edlich received the Distinguished Public Service Award for Contributions to Emergency Medicine by the US Public Health Service.
AMP + diphosphate + GMP + L-glutamate The 4 substrates of this enzyme are ATP, xanthosine 5'-phosphate, L-glutamine, and H2O, whereas its 4 products are AMP, diphosphate, GMP, and L-glutamate. This enzyme belongs to the family of ligases, specifically those forming carbon-nitrogen bonds carbon-nitrogen ligases with glutamine as amido-N-donor. The systematic name of this enzyme class is xanthosine-5'-phosphate:L-glutamine amido-ligase (AMP-forming). This enzyme participates in purine metabolism and glutamate metabolism. At least one compound, Psicofuranin is known to inhibit this enzyme.
His publications also highlight the importance of patient happiness, as well as the well-being of the treating physician. Strengthening family support, advancing social acceptance, and addressing patient emotions are other elements he considers essential to delivering person-centred care.69 He has also highlighted the value of indigenous methods for lifestyle modification and personal hygiene in improving person-centred care.123,166 Kalra has proposed several frameworks to help clinicians integrate the above principles into routine practice.129,161,162 These frameworks have been widely cited. In collaboration with researchers in Morocco, he published the SURE framework outlining the “glycaemic personality” of patients, enabling more tailored therapeutic choices. In another publication, he described the Motivation–Opportunity–Capability (MOC) model for obesity care, underscoring the importance of understanding patient behaviour and aligning therapeutic approaches with their opportunities and capabilities. Kalra’s contribution to original research includes participation in multicentric international collaborative studies that have advanced understanding of person-centred management. In the three-year, pan-India longitudinal study on diabetes outcomes (the LANDMARC trial), data are being collected on trends in diabetic complications, physician treatment strategies, and correlations between treatment, control, and complications in the Indian setting.
Sample preparation for mass spectrometry is used for the optimization of a sample for analysis in a mass spectrometer (MS). Each ionization method has certain factors that must be considered for that method to be successful, such as volume, concentration, sample phase, and composition of the analyte solution. Quite possibly the most important consideration in sample preparation is knowing what phase the sample must be in for analysis to be successful. In some cases the analyte itself must be purified before entering the ion source. In other situations, the matrix, or everything in the solution surrounding the analyte, is the most important factor to consider and adjust. Often, sample preparation itself for mass spectrometry can be avoided by coupling mass spectrometry to a chromatography method, or some other form of separation before entering the mass spectrometer. In some cases, the analyte itself must be adjusted so that analysis is possible, such as in protein mass spectrometry, where usually the protein of interest is cleaved into peptides before analysis, either by in-gel digestion or by proteolysis in solution.
Sources: en.wikipedia.org
== Career == In 1977, Bowman joined International Plasma Corporation of Hayward, California as chief financial officer and general manager of its analytical instrument division. International Plasma Corporation owned Durrum Instrument Corporation, an instrumentation company that had purchased exclusive rights to an emergent technology, Ion chromatography, from Dow Chemical Company. Initial research by Hamish Small and others at the Dow Physical Research Laboratory in Midland, Michigan suggested that inorganic ion analysis would be superior to commonly used wet chemical techniques, but Dow was not interested in pursuing the idea. Bowman became interested in the potential of ion chromatography (IC) while at International Plasma Corporation. In 1980, Smith-Kline acquired International Plasma Corporation. The IC division was spun off as a separate company, under the name Dionex Corporation, in a leveraged buyout (LBO) led by A. Blaine Bowman. Bowman became the president and CEO of the new company, which was incorporated in California in 1980. The company was reincorporated in Delaware in 1986. Dionex began to trade publicly as of 1982. Under Bowman's leadership, Dionex made important advances both scientifically and economically. The company directed up to nine percent of its revenues back into its ongoing research and development program.
Flag Fen, east of Peterborough, England, is a Bronze Age site which was constructed about 3,500 years ago and consists of more than 60,000 timbers arranged in five very long rows, creating a wooden causeway (around 1 km or 0.6 mi long) across the wet fenland. Part-way across the structure a small island was formed. Items associated with it have led scholars to conclude that the island was of religious significance. Archaeological work began in 1982 at the site, which is located 800 m (0.5 mi) east of Fengate. Flag Fen is now part of the Greater Fens Museum Partnership. A visitor centre has been constructed on site and some areas have been reconstructed, including a typical Iron Age roundhouse dwelling. A section of the original causeway is preserved in wet conditions in the Preservation Hall.
Newsom declared a state of emergency on March 4, 2020, after the first death in California attributable to the novel SARS-CoV-2 coronavirus disease (COVID-19). His stated intention was to help California prepare for and contain COVID-19's spread. The emergency declaration allowed state agencies to more easily procure equipment and services, share information on patients and alleviated restrictions on the use of state-owned properties and facilities. Newsom also announced that mitigation policies for the state's estimated 108,000 unsheltered homeless people would be prioritized, with a significant push to move them indoors. Newsom issued an executive order that allowed the state to commandeer hotels and medical facilities to treat COVID-19 patients and permitted government officials to hold teleconferences in private without violating open meeting laws. He also directed local school districts to make their own decisions on school closures, but used an executive order to ensure students' needs would be met whether or not their school was physically open. The U.S. Department of Agriculture approved the Newsom administration's request to offer meal service during school closures, which included families being able to pick up those meals at libraries, parks, or other off-campus locations. Roughly 80% of students at California's public schools receive free or reduced-price meals. This executive order included continued funding for remote learning opportunities and child care options during workday hours.
=== Protein degradation === Protein degradation may take place intracellularly or extracellularly. In digestion of food, digestive enzymes may be released into the environment for extracellular digestion whereby proteolytic cleavage breaks proteins into smaller peptides and amino acids so that they may be absorbed and used. In animals the food may be processed extracellularly in specialized organs or guts, but in many bacteria the food may be internalized via phagocytosis. Microbial degradation of protein in the environment can be regulated by nutrient availability. For example, limitation for major elements in proteins (carbon, nitrogen, and sulfur) induces proteolytic activity in the fungus Neurospora crassa as well as in of soil organism communities. Proteins in cells are broken into amino acids. This intracellular degradation of protein serves multiple functions: It removes damaged and abnormal proteins and prevents their accumulation. It also serves to regulate cellular processes by removing enzymes and regulatory proteins that are no longer needed. The amino acids may then be reused for protein synthesis.
Although the mechanism of this reaction has not been fully elucidated, it is speculated that the use of an electron-deficient phosphonate accelerates elimination of the oxaphosphatane intermediate. This renders the initial addition of the phosphonate-stabilized carbanion to the aldehyde effectively irreversible, leading to Z-selectivity in analogy to the standard Wittig reaction.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.
No. Cardarine is not an anabolic steroid; it belongs to a different chemical class that targets PPARδ. Steroids act primarily through androgen receptors, while cardarine acts through a nuclear receptor involved in metabolism.
Some rodent studies reported increased endurance and changes in fat metabolism after cardarine exposure. Long-term studies in animals also raised concerns about cancer in certain tissues. Human trial data are limited, so these findings cannot be directly translated to people.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.